After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the
After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium (BUSINESS WIRE) The Janssen Pharmaceutica.
Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Operator
Greetings and welcome to the TG Therapeutics Fourth Quarter and Year-End 2020 Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. [Operator Instructions]
I would now like to turn the conference over to your host, Jenna Bosco, Senior Vice President of Corporate Communications. Please go ahead.
Jenna Bosco
Senior Vice President of Corporate Communications
Thank you. Welcome everyone, and thanks for joining us this morning. I m Jenna Bosco and with me today to discuss the fourth quarter and year-end 2020 financial results and provide a business update are Sean Power, our Chief Financial Officer; Michael Weiss, our Executive Chairman and Chief Executive Officer; and Adam Waldman, our Chief Commercialization Officer.